• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
A gavel in the foreground with the scale of justice in the background
Biotech

Pioneer of China NewCo model sued over double-dealing

Hengrui's former business development head faces a New York lawsuit over allegations her consulting firm secretly served two direct competitors.
Angus Liu Sep 25, 2026 8:40am
als

Beyond clinical endpoints: Rethinking ALS drug development through disease biology

Brought to you by Neurizon Therapeutics
RNA cell

ADARx scores upsized $446M IPO, while City maps out Nasdaq plans

Sep 25, 2026 2:46am
Lundbeck
Favicon Fierce Pharma

Lundbeck relocating US headquarters to Boston in innovation move

Sep 25, 2026 10:41am
Illustration for Fierces Chutes  Ladders feature showing a blue city skyline with executives making career moves o

Travere chief makes way for former Amicus CEO—Chutes & Ladders

Sep 25, 2026 8:30am
Close-up of shredded document

Indivior ends PAM drug collab with Addex ahead of merger

Sep 25, 2026 5:23am
More News

Novo inks $1.3B deal to unlock long-acting obesity injectables

Sep 25, 2026 4:53am

Genentech inks $1.5B bispecific pact with fast-rising Earendil

Sep 25, 2026 2:51am

Overton backs vaccines, mifepristone in confirmation hearing

Sep 24, 2026 2:32pm

NIH debuts tool to help scientists navigate biomedical database

Sep 24, 2026 2:00pm
See more stories
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings